Devyn Smith, Arbor Biotechnologies CEO
May 7, 2024 07:00 AM EDTUpdated 02:02 PM
Deals
R&D
Law

Ex­clu­sive: Feng Zhang CRISPR start­up gath­ers patents, lock­ing up rights to fam­i­ly of edit­ing tech

Ryan Cross

Senior Science Correspondent

In the bid to lock up patent rights to a grow­ing suite of gene edit­ing tech­nolo­gies, Ar­bor Biotech­nolo­gies has ac­quired a small start­up found­ed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times